Rebecca Stern, MD
Gynecology · Boca Raton, FLNPI 1326050444
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $782 and has fallen 60.6% since, to $308 in 2025.
Across 203 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$690
- Astellas Pharma US Inc$469
- Mayne Pharma Commercial LLC$427
- Exeltis, USA Inc.$277
- Evofem Biosciences, Inc.$263
- Millicent US Inc$182
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$231%
- Food & beverage$3,69393%
- Education$2446%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $690 |
| Astellas Pharma US Inc | 14 | $469 |
| Mayne Pharma Commercial LLC | 28 | $427 |
| Exeltis, USA Inc. | 16 | $277 |
| Evofem Biosciences, Inc. | 15 | $263 |
| Millicent US Inc | 9 | $182 |
| Hologic Sales And Service, LLC | 8 | $173 |
| Dilon Technologies, Inc. | 1 | $151 |
| Therapeuticsmd, Inc. | 9 | $145 |
| Caldera Medical, Inc | 2 | $136 |
| Bayer | 5 | $123 |
| Myovant Sciences Inc. | 1 | $118 |
| Sumitomo Pharma America, Inc. | 5 | $112 |
| Avion Pharmaceuticals | 6 | $79 |
| Pfizer | 3 | $64 |
| Lupin Inc. | 3 | $51 |
| Ascend Therapeutics US, LLC | 3 | $42 |
| Coopersurgical, Inc. | 3 | $42 |
| Shield Therapeutics Inc | 2 | $40 |
| Agile Therapeutics, Inc. | 3 | $38 |
| Duchesnay USA Incorporated | 2 | $37 |
| Roche Diagnostics Corporation | 2 | $29 |
| Galderma Laboratories, L.p. | 2 | $29 |
| Hologic Inc | 1 | $28 |
| Virtus Pharmaceuticals LLC | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Palette Life Sciences, Inc. | 1 | $23 |
| Aspira Women's Health Inc | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Mycovia Pharmaceuticals, Inc. | 1 | $18 |
| Sanara Medtech Inc. | 1 | $16 |
| Meditrina | 1 | $14 |
| Scynexis, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HemoBlast Bellows$151
- MYFEMBREE$118
How this compares
$3,979 in reported general payments places this provider in the 85th percentile of 290 gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 108 | $10,702 |
| PremarinEstrogens, Conjugated | 20 | $10,398 |
| VeozahFezolinetant | 11 | $5,910 |
| ValacyclovirValacyclovir Hcl | 35 | $1,673 |
| Estradiol (Twice Weekly)Estradiol | 14 | $1,028 |
| Terconazole | 29 | $936 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 40 | $776 |
| Raloxifene Hcl | 17 | $515 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 45 | $468 |
| Alendronate Sodium | 29 | $157 |
| Ciprofloxacin Hcl | 25 | $141 |
| Fluconazole | 28 | $110 |
| Cephalexin | 20 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $64 | $10,39820 claims |
| Astellas Pharma US IncVeozah | $469 | $5,91011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 gynecology providers in Florida.
Other gynecology in Boca Raton
- Michael FleischerBoca Raton$8K
- Alexandria AngelidesBoca Raton$3K
- Aileen CaceresKissimmee$406K
- Parveen VahoraNew Port Richey$327K
- James KondrupVenice$310K
- Andrea GallowayThe Villages$252K
- Jessica VaughtOrlando$129K
- Steven ChavoustieMiami$113K
- Marshall BovelskyMelbourne$52K
- Minda NeimarkFt Lauderdale$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.